Inhibition of BCR-ABL with kinase inhibitors such as imatinib mesylate in the treatment of Ph+ CML is the current standard therapy, but it is highly effective in controlling but not curing the disease. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.